Mismatch repair deficient colorectal cancer in the era of personalized treatment

Nature Reviews Clinical Oncology

Volumn 7, Issue 4, 2010, Pages 197-208

  Hewish, Madeleine ^a   Lord, Christopher J ^a   Martin, Sarah A ^a   Cunningham, David ^b   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; MISMATCH REPAIR PROTEIN PMS2; MITOMYCIN C; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; RALTITREXED; THYMIDINE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; GAIN OF FUNCTION MUTATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ILEORECTAL ANASTOMOSIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CONFIDENCE INTERVALS; DNA MISMATCH REPAIR; HUMANS; MUTATION; PHENOTYPE; PLATINUM COMPOUNDS; PROGNOSIS;

EID: 77950521000     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.18     Document Type: Review

References (139)

1. Jemal, A. et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335-346 (2006).
3. Parsons, R. et al. Hypermutability and mismatch repair deficiency in ReR+ tumor cells. Cell 75, 1227-1236 (1993). (Pubitemid 24006118)
4. Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J. & Meuth, M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl Acad. Sci. USA 91, 6319-6323 (1994). (Pubitemid 24200652)
5. Duval, A. & Hamelin, R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 62, 2447-2454 (2002). (Pubitemid 34462716)
6. Jung, B. H. et al. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin. Gastroenterology 132, 633-644 (2007).
7. Miquel, C. et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26, 5919-5926 (2007).
8. Ionov, Y., Matsui, S. & Cowell, J. K. A role for p300/CReB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc. Natl Acad. Sci. USA 101, 1273-1278 (2004). (Pubitemid 38182679)
9. Loughrey, M. B. et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam. Cancer 6, 301-310 (2007).
10. Kim, N. G. et al. Identification of MARCKS, FLJ11383 and TAF1B as putative novel target genes in colorectal carcinomas with microsatellite instability. Oncogene 21, 5081-5087 (2002).
11. Ropero, S. et al. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 27, 4008-4012 (2008). (Pubitemid 351913637)
12. Kloor, M. et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 65, 6418-6424 (2005). (Pubitemid 40994430)
13. Johannsdottir, J. T. et al. The effect of mismatch repair deficiency on tumourigenesis; microsatellite instability affecting genes containing short repeated sequences. Int. J. Oncol. 16, 133-139 (2000).
14. Palomaki, G. e., McClain, M. R., Melillo, S., Hampel, H. L. & Thibodeau, S. N. eGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11, 42-65 (2009).
15. Lynch, H. T., Lynch, J. F., Lynch, P. M. & Attard, T. Hereditary colorectal cancer syndromes: molecular genetics, genetic counseling, diagnosis and management. Fam. Cancer 7, 27-39 (2008).
16. Imai, K. & Yamamoto, H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29, 673-680 (2008). (Pubitemid 351494153)
17. Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23, 609-618 (2005). (Pubitemid 46224239)
18. Knudson, A. G. Hereditary cancer: two hits revisited. J. Cancer Res. Clin. Oncol. 122, 135-140 (1996).
19. Hampel, H. et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J. Clin. Oncol. 26, 5783-5788 (2008).
20. Tomlinson, I. P., Roylance, R. & Houlston, R. S. Two hits revisited again. J. Med. Genet. 38, 81-85 (2001). (Pubitemid 32171338)
21. Suter, C. M., Martin, D. I. & Ward, R. L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat. Genet. 36, 497-501 (2004).
22. Hitchins, M. P. et al. Inheritance of a cancerassociated MLH1 germ-line epimutation. N. Engl. J. Med. 356, 697-705 (2007). (Pubitemid 46257232)
23. Chan, T. L. et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat. Genet. 38, 1178-1183 (2006). (Pubitemid 44470364)
24. Wimmer, K. & etzler, J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum. Genet. 124, 105-122 (2008).
25. Scott, R. H. et al. Familial T-cell non-Hodgkin lymphoma caused by biallelic MSH2 mutations. J. Med. Genet. 44, e83 (2007).
26. Alexander, J. et al. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158, 527-535 (2001). (Pubitemid 32158613)
27. Jass, J. R. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam. Cancer 3, 93-100 (2004).
28. Gatalica, Z. & Torlakovic, e. Pathology of the hereditary colorectal carcinoma. Fam. Cancer 7, 15-26 (2008).
29. Ogino, S. & Goel, A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 10, 13-27 (2008). (Pubitemid 351184831)
30. Shia, J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J. Mol. Diagn. 10, 293-300 (2008). (Pubitemid 352019113)
31. Zhang, L. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J. Mol. Diagn. 10, 301-307 (2008). (Pubitemid 352019114)
32. Laghi, L., Bianchi, P. & Malesci, A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27, 6313-6321 (2008).
33. Umar, A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96, 261-268 (2004). (Pubitemid 38256271)
34. Boland, C. R., Koi, M., Chang, D. K. & Carethers, J. M. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam. Cancer 7, 41-52 (2008).
35. Chen, S. et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296, 1479-1487 (2006). (Pubitemid 44465512)
36. Balmaña, J. et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296, 1469-1478 (2006). (Pubitemid 44465511)
37. Barnetson, R. A. et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354, 2751-2763 (2006).
38. Julié, C. et al. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening. Am. J. Gastroenterol. 103, 2825-2835 (2008).
39. Dunlop, M. G. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 51 (Suppl. 5), v21-v27 (2002).
40. van Duijvendijk, P. et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. Br. J. Surg. 87, 590-596 (2000). (Pubitemid 30261094)
41. Chau, I. et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J. Clin. Oncol. 24, 668-674 (2006). (Pubitemid 46630432)
42. Koopman, M. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100, 266-273 (2009).
43. Braun, M. S. et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26, 2690-2698 (2008).
44. Jover, R. et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 45, 365-373 (2008).
45. Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96 (2009).
46. Tol, J., Nagtegaal, I. D. & Punt, C. J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98-99 (2009).
47. French, A. J. et al. Prognostic significance of defective mismatch repair and BRAF v600e in patients with colon cancer. Clin. Cancer Res. 14, 3408-3415 (2008).
48. Trautmann, K. et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin. Cancer Res. 12, 6379-6385 (2006). (Pubitemid 44799708)
49. Goel, A. et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 63, 1608-1614 (2003). (Pubitemid 36373651)
50. Walther, A., Houlston, R. & Tomlinson, I. Association between chromosomal instability and prognosis in colorectal cancer: a metaanalysis. Gut 57, 941-950 (2008). (Pubitemid 351919529)
51. Sinicrope, F. A. et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131, 729-737 (2006).
52. Choi, S. W. et al. Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin. Cancer Res. 8, 2311-2322 (2002). (Pubitemid 34753606)
53. Nicum, S., Midgley, R. & Kerr, D. J. Chemotherapy for colorectal cancer. J. R. Soc. Med. 93, 416-419 (2000). (Pubitemid 30649437)
54. Walko, C. M. & Lindley, C. Capecitabine: a review. Clin. Ther. 27, 23-44 (2005). (Pubitemid 40347299)
55. Meyers, M. et al. DNA mismatch repairdependent response to fluoropyrimidinegenerated damage. J. Biol. Chem. 280, 5516-5526 (2005). (Pubitemid 40280029)
56. Parker, W. B. & Cheng, Y. C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 48, 381-395 (1990).
57. Aebi, S. et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 3, 1763-1767 (1997). (Pubitemid 27444715)
58. Remick, S. C. et al. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res. 50, 2667-2672 (1990).
59. Carethers, J. M. et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117, 123-131 (1999).
60. Tokunaga, e., Oda, S., Fukushima, M., Maehara, Y. & Sugimachi, K. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur. J. Cancer 36, 1998-2006 (2000).
61. Meyers, M., Wagner, M. W., Hwang, H. S., Kinsella, T. J. & Boothman, D. A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 61, 5193-5201 (2001). (Pubitemid 32681553)
62. Arnold, C. N., Goel, A. & Boland, C. R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer 106, 66-73 (2003). (Pubitemid 36750389)
63. Pocard, M., Bras-Gonçalves, R., Hamelin, R., Northover, J. & Poupon, M. F. Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status. Anticancer Res. 20, 85-90 (2000). (Pubitemid 30189737)
64. Tajima, A., Hess, M. T., Cabrera, B. L., Kolodner, R. D. & Carethers, J. M. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil- modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127, 1678-1684 (2004). (Pubitemid 39575846)
65. Gray, R. G. et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients [abstract]. J. Clin. Oncol. 22, a3501 (2004).
66. Sargent, D. J. et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials [abstract]. J. Clin. Oncol. 26, a4008 (2008).
67. Moran, R. G. & Scanlon, K. L. Scheduledependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res. 51, 4618-4623 (1991).
68. Stevenson, H. C., Green, I., Hamilton, J. M., Calabro, B. A. & Parkinson, D. R. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J. Clin. Oncol. 9, 2052-2066 (1991).
69. Sany, J. Immunological treatment of rheumatoid arthritis. Clin. Exp. Rheumatol. 8 (Suppl. 5), 81-88 (1990). (Pubitemid 20342847)
70. Tougeron, D. et al. Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod. Pathol. 22, 1186-1195 (2009).
71. Benson, A. B. 3rd. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin. Cancer Res. 13, 6913s-6920s (2007).
72. Des Guetz, G., Uzzan, B., Nicolas, P., Schischmanoff, O. & Morere, J. F. Microsatellite instability: a predictive marker in metastatic colorectal cancer? Target. Oncol. 4, 57-62 (2009).
73. Popat, S., Matakidou, A. & Houlston, R. S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J. Clin. Oncol. 22, 529-536 (2004). (Pubitemid 41079782)
74. Sinicrope, F. A. et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin. Cancer Res. 12, 2738-2744 (2006). (Pubitemid 43752111)
75. Popat, S., Wort, R. & Houlston, R. S. Interrelationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. BMC Cancer 6, 150 (2006). (Pubitemid 44082230)
76. Calascibetta, A. et al. Thymidylate synthase gene promoter polymorphisms are associated with TSmRNA expressions but not with microsatellite instability in colorectal cancer. Anticancer Res. 24, 3875-3880 (2004). (Pubitemid 40468679)
77. van Rijnsoever, M., elsaleh, H., Joseph, D., McCaul, K. & Iacopetta, B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9, 2898-2903 (2003). (Pubitemid 36993247)
78. Shen, L. et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 13, 6093-6098 (2007). (Pubitemid 350075067)
79. Ogino, S. et al. evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 9, 305-314 (2007). (Pubitemid 47305066)
80. Weisenberger, D. J. et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006). (Pubitemid 43980599)
81. Capdevila, J. et al. Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev. Anticancer Ther. 8, 1223-1236 (2008).
82. Aebi, S. et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56, 3087-3090 (1996). (Pubitemid 26199755)
83. Drummond, J. T., Anthoney, A., Brown, R. & Modrich, P. Cisplatin and adriamycin resistance are associated with MutL? and mismatch repair deficiency in an ovarian tumor cell line. J. Biol. Chem. 271, 19645-19648 (1996). (Pubitemid 26281694)
84. Fink, D. et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57, 1841-1845 (1997). (Pubitemid 27209707)
85. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413 (2001).
86. Rodriguez, R. et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin. Cancer Res. 14, 5476-5483 (2008).
87. Fedier, A. et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer 93, 571-576 (2001). (Pubitemid 32701417)
88. Takahashi, T. et al. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett. 220, 85-93 (2005). (Pubitemid 40312021)
89. Papouli, e., Cejka, P. & Jiricny, J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 64, 3391-3394 (2004). (Pubitemid 38657910)
90. Jacob, S., Aguado, M., Fallik, D. & Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 61, 6555-6562 (2001). (Pubitemid 32783264)
91. vilar, e. et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer 99, 1607-1612 (2008).
92. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 6, 789-802 (2006). (Pubitemid 44450467)
93. Bras-Gonçalves, R. A. et al. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br. J. Cancer 82, 913-923 (2000). (Pubitemid 30085246)
94. Bertagnolli, M. M. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27, 1814-1821 (2009).
95. Fiumicino, S. et al. Sensitivity to DNA crosslinking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int. J. Cancer 85, 590-596 (2000). (Pubitemid 30075141)
96. Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R. & Bignami, M. N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res. 58, 135-141 (1998). (Pubitemid 28027728)
97. Chong, G. et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br. J. Cancer 93, 510-514 (2005). (Pubitemid 43079992)
98. Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wildtype metastatic colorectal cancer. Br. J. Cancer 101, 715-721 (2009).
99. Rajagopalan, H. et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934 (2002). (Pubitemid 34976022)
100. Wendum, D. et al. Mucinous colon carcinomas with microsatellite instability have a lower microvessel density and lower vascular endothelial growth factor expression. Virchows Arch. 442, 111-117 (2003). (Pubitemid 36337657)
101. Wynter, C. v. et al. Angiogenic factor veGF is decreased in human colorectal neoplasms showing DNA microsatellite instability. J. Pathol. 189, 319-325 (1999).
102. vilar, e. et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKTmammalian target of rapamycin pathway. Clin. Cancer Res. 15, 2829-2839 (2009).
103. Bolderson, e., Scorah, J., Helleday, T., Smythe, C. & Meuth, M. ATM is required for the cellular response to thymidine induced replication fork stress. Hum. Mol. Genet. 13, 2937-2945 (2004). (Pubitemid 39585226)
104. Berry, S. e. et al. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res. 60, 5773-5780 (2000).
105. Kinsella, T. J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin. Cancer Res. 15, 1853-1859 (2009).
106. Liu, L. & Gerson, S. L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623-627 (2004).
107. Lord, C. J. & Ashworth, A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363-369 (2008).
108. Choi, M. Y., Lauwers, G. Y., Hur, C., Willett, C. G. & Chung, D. C. Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 68, 1584 (2007). (Pubitemid 47176835)
109. Kaelin, W. G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
110. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
111. edelmann, W. et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res. 60, 803-807 (2000). (Pubitemid 30129505)
112. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
113. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
114. Bryant, H. e. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 434, 913-917 (2005).
115. Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323-337 (2009).
116. vilar, e. et al. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer [abstract]. J. Clin. Oncol. 15, a11028 (2009).
117. Swanton, C., Tomlinson, I. & Downward, J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 5, 818-823 (2006). (Pubitemid 44145573)
118. Pazdur, R. et al. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann. Oncol. 5, 468-470 (1994). (Pubitemid 24159656)
119. Swanton, C. & Caldas, C. Molecular classification of solid tumours: towards pathwaydriven therapeutics. Br. J. Cancer 100, 1517-1522 (2009).
120. Baird, R. D. & Kaye, S. B. Drug resistance reversal-are we getting closer? Eur. J. Cancer 39, 2450-2461 (2003).
121. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008). (Pubitemid 351723664)
122. Solit, D. B. et al. BRAF mutation predicts sensitivity to MeK inhibition. Nature 439, 358-362 (2006).
123. Gifford, G., Paul, J., vasey, P.A., Kaye, S.B. & Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10, 4420-4426 (2004). (Pubitemid 38878884)
124. Hofseth, L. J. et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 112, 1887-1894 (2003).
125. Nakamura, H. et al. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DeC1 and DeC2. Oncogene 27, 4200-4209 (2008). (Pubitemid 351969910)
126. Svrcek, M. et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J. Clin. Oncol. 25, 4231-4238 (2007). (Pubitemid 47548563)
127. Li, G. M. Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85-98 (2008).
128. Alazzouzi, H. et al. Mechanisms of inactivation of the receptor tyrosine kinase ePHB2 in colorectal tumors. Cancer Res. 65, 10170-10173 (2005). (Pubitemid 41743705)
129. Ollikainen, M. et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int. J. Cancer 121, 915-920 (2007). (Pubitemid 47106226)
130. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22, 1931-1937 (2001). (Pubitemid 34065386)
131. Kim, J. C. et al. evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int. J. Colorectal Dis. 24, 209-218 (2009).
132. Senter, L. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 135, 419-429 (2008).
133. Lynch, H. T. et al. Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur. J. Hum. Genet. 14, 390-402 (2006).
134. Kim, G. P. et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25, 767-772 (2007).
135. Jover, R. et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 45, 365-373 (2009).
136. Ribic, C. M. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349, 247-257 (2003).
137. Tejpar, S. et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-Lv or 5FU-Lv and irinotecan (PeTACC 3-eORTC 40993-SAKK 60/00 trial) [abstract]. J. Clin. Oncol. 27, a4008 (2009).
138. Fallik, D. et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63, 5738-5744 (2003). (Pubitemid 37187470)
139. Charara, M. et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res. 24, 3161-3167 (2004). (Pubitemid 39390968)